PI3K-AKT-mTOR pathway and cancer

被引：32

作者：

Coutte, Laetitia ^{[1
]}

Dreyer, Chantal ^{[1
]}

Sablin, Marie-Paule ^{[1
]}

Faivre, Sandrine ^{[1
]}

Raymond, Eric ^{[1
]}

机构：

[1] Hop Beaujon, Serv Interhosp Cancerol, F-92118 Clichy, France

来源：

BULLETIN DU CANCER | 2012年 / 99卷 / 02期

关键词：

PI3K-AKT; mTOR; everolimus; renal cancer; RENAL-CELL CARCINOMA; PHASE-II TRIAL; SINGLE-AGENT TEMSIROLIMUS; EVERY; WEEKS; MAMMALIAN TARGET; MESENCHYMAL TRANSITION; RAD001; EVEROLIMUS; MTOR INHIBITOR; RAPAMYCIN; CCI-779;

D O I：

10.1684/bdc.2011.1384

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

PI3K/AKT/mTOR pathway is an intracellular signalling pathway composed of different kinases. Many protein mutations are described in that pathway, and are responsible of dysregulation of cell growth, proliferation, survival and angiogenesis. Rapamycin is an antibiotic inhibiting mTOR. Different analogs of rapamycin are developped or being developped in antitumoral therapy, in which temsirolimus, everolimus and deforolimus, demonstrated antitumoral activity in renal cancer and mantle cell lymphoma, and many clinical trials are in progress in other tumors. In the future, predictive factors of response need to be identified; patient selection and associations with chemotherapy or with other targeted therapies should be explored.

引用

页码：173 / 180

页数：8

共 35 条

[1]

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma [J].

Aguirre, D ;

Boya, P ;

Bellet, D ;

Faivre, S ;

Troalen, F ;

Benard, J ;

Saulnier, P ;

Hopkins-Donaldson, S ;

Zangemeister-Wittke, U ;

Kroemer, G ;

Raymond, E .

APOPTOSIS, 2004, 9 (06) :797-805

[2]

Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines [J].

Aissat, Nasredine ;

Le Tourneau, Christophe ;

Ghoul, Aida ;

Serova, Maria ;

Bieche, Ivan ;

Lokiec, Francois ;

Raymond, Eric ;

Faivre, Sandrine .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (02) :305-313

[3]

A Phase 2 Study With a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients With Metastatic Clear Cell Renal Cell Cancer [J].

Amato, Robert J. ;

Jac, Jaroslaw ;

Giessinger, Sarah ;

Saxena, Somyata ;

Willis, James P. .

CANCER, 2009, 115 (11) :2438-2446

[4]

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma - A phase 2 trial in the North Central Cancer Treatment Group [J].

Ansell, Stephen M. ;

Inwards, David J. ;

Rowland, Kendrith M., Jr. ;

Flynn, Patrick J. ;

Morton, Roscoe F. ;

Moore, Dennis F., Jr. ;

Kaufmann, Scott H. ;

Ghobrial, Irene ;

Kurtin, Paul J. ;

Maurer, Matthew ;

Allmer, Christine ;

Witzig, Thomas E. .

CANCER, 2008, 113 (03) :508-514

[5]

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[6]

Renal-cell carcinoma - Molecular pathways and therapies [J].

Brugarolas, James .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :185-187

[7]

Decaens T, ASCO GASTR CANC S 20

[8]

A Molecular Link between AKT Regulation and Chemotherapeutic Response [J].

Dibble, Christian C. ;

Manning, Brendan D. .

CANCER CELL, 2009, 16 (03) :178-180

[9]

Topics in mTOR pathway and its inhibitors [J].

Dreyer, C. ;

Sablin, M. -P. ;

Faivre, S. ;

Raymond, E. .

BULLETIN DU CANCER, 2009, 96 (01) :87-94

[10]

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus [J].

Duran, I. ;

Siu, L. L. ;

Oza, A. M. ;

Chung, T. -B. ;

Sturgeon, J. ;

Townsley, C. A. ;

Pond, G. R. ;

Seymour, L. ;

Niroumand, M. .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (12) :1875-1880

← 1 2 3 4 →